Skip to content

Effects of Hijama Bil Shart (Wet Cupping)in the Management of Zaght al-Dam Qawi Ibtedai (Primary Hypertension)

Therapeutic Evaluation of Effects of Hijama Bil Shart in the Management of Zaghtuddam Qawi Ibtedai (Primary Hypertension) in comparison with Amlodipine.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026872
Enrollment
60
Registered
2020-07-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Hijama Bil Shart (Cupping with scarification ): Hijama Bil Shart (Cupping with scarification ) in test Group, on the Interascapular one cup on each site in every 15 days Control Interve

Sponsors

CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1- Patients with primary mild hypertension (ranging between systolic pressure 140 to 159 mmHg and /or diastolic pressure 90 to 99 mmHg). 2- Age between 28 to 65 years 3- Male/Female/Irrespective gender 4- Chronicity of disease up to 10 year

Exclusion criteria

Exclusion criteria: Physiological Status 1- Patients below 28 and above 65 years of age. 2- Pregnancy and lactation. 3- Menstruation and postpartum hemorrhage. Pathological Status 4- Secondary Hypertension. 5- Moderate and Severe Hypertension. 6- Diabetes Mellitus. 7- History of bleeding disorders. 8- Anemia. 9- Bleeding piles. 10- Chronic renal failure and liver failure. 11- History of Myocardial infarction and Ischemic Heart Disease. 12- Bronchial Asthma and COPD. 13- HIV and/ or HbsAg positive.

Design outcomes

Primary

MeasureTime frame
Relief in sign symptoms of primary HypertensionTimepoint: 60 days

Secondary

MeasureTime frame
Haematological and biochemical assessment for safetyTimepoint: 60 days

Countries

India

Contacts

Public ContactDrSheeraz Mushtaq

Regional Research Institute of Unani Medicine (RRIUM), University of Kashmir, Srinagar. J&K

naquibislam@gmail.com7006725908

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026